 Antineoplastic Agents
"Antineoplastic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
| Descriptor ID |
D000970
|
| MeSH Number(s) |
D27.505.954.248
|
| Concept/Terms |
Antineoplastic Agents- Antineoplastic Agents
- Agents, Antineoplastic
- Antineoplastic Drugs
- Drugs, Antineoplastic
- Antineoplastics
- Chemotherapeutic Anticancer Drug
- Drug, Chemotherapeutic Anticancer
- Antitumor Drugs
- Drugs, Antitumor
- Cancer Chemotherapy Agents
- Agents, Cancer Chemotherapy
- Chemotherapy Agents, Cancer
- Cancer Chemotherapy Drugs
- Chemotherapy Drugs, Cancer
- Drugs, Cancer Chemotherapy
- Chemotherapeutic Anticancer Agents
- Agents, Chemotherapeutic Anticancer
- Anticancer Agents
- Agents, Anticancer
- Antitumor Agents
- Agents, Antitumor
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents".
This graph shows the total number of publications written about "Antineoplastic Agents" by people in this website by year, and whether "Antineoplastic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1981 | 1 | 1 | 2 | | 1982 | 1 | 0 | 1 | | 1983 | 0 | 1 | 1 | | 1985 | 0 | 1 | 1 | | 1988 | 1 | 0 | 1 | | 1998 | 0 | 1 | 1 | | 1999 | 1 | 0 | 1 | | 2000 | 1 | 0 | 1 | | 2002 | 0 | 1 | 1 | | 2003 | 1 | 1 | 2 | | 2007 | 1 | 2 | 3 | | 2008 | 1 | 1 | 2 | | 2009 | 6 | 0 | 6 | | 2010 | 5 | 5 | 10 | | 2011 | 3 | 1 | 4 | | 2012 | 3 | 0 | 3 | | 2013 | 5 | 2 | 7 | | 2014 | 4 | 2 | 6 | | 2015 | 3 | 3 | 6 | | 2016 | 2 | 0 | 2 | | 2017 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Antineoplastic Agents" by people in Profiles.
-
Yang L, Bose S, Ngo AH, Do LH. Innocent But Deadly: Nontoxic Organoiridium Catalysts Promote Selective Cancer Cell Death. ChemMedChem. 2017 Feb 20; 12(4):292-299.
-
Yang L, Moghaddas S, Dezvareh H, Belkacemi L, Bark SJ, Bose RN, Do LH. Insights into the anti-angiogenic properties of phosphaplatins. J Inorg Biochem. 2016 Nov; 164:5-16.
-
Murray MJ. Thanks for sharing: the bumpy road towards truly open data. BMJ. 2016 Mar 02; 352:i849.
-
Asim M, Massie CE, Orafidiya F, Pértega-Gomes N, Warren AY, Esmaeili M, Selth LA, Zecchini HI, Luko K, Qureshi A, Baridi A, Menon S, Madhu B, Escriu C, Lyons S, Vowler SL, Zecchini VR, Shaw G, Hessenkemper W, Russell R, Mohammed H, Stefanos N, Lynch AG, Grigorenko E, D'Santos C, Taylor C, Lamb A, Sriranjan R, Yang J, Stark R, Dehm SM, Rennie PS, Carroll JS, Griffiths JR, Tavaré S, Mills IG, McEwan IJ, Baniahmad A, Tilley WD, Neal DE. Choline Kinase Alpha as an Androgen Receptor Chaperone and Prostate Cancer Therapeutic Target. J Natl Cancer Inst. 2016 May; 108(5).
-
Delitto D, Black BS, Sorenson HL, Knowlton AE, Thomas RM, Sarosi GA, Moldawer LL, Behrns KE, Liu C, George TJ, Trevino JG, Wallet SM, Hughes SJ. The inflammatory milieu within the pancreatic cancer microenvironment correlates with clinicopathologic parameters, chemoresistance and survival. BMC Cancer. 2015 Oct 24; 15:783.
-
Vippila MR, Ly PK, Cuny GD. Synthesis and Antiproliferative Activity Evaluation of the Disulfide-Containing Cyclic Peptide Thiochondrilline C and Derivatives. J Nat Prod. 2015 Oct 23; 78(10):2398-404.
-
Shor B, Kahler J, Dougher M, Xu J, Mack M, Rosfjord E, Wang F, Melamud E, Sapra P. Enhanced Antitumor Activity of an Anti-5T4 Antibody-Drug Conjugate in Combination with PI3K/mTOR inhibitors or Taxanes. Clin Cancer Res. 2016 Jan 15; 22(2):383-94.
-
Najjar M, Suebsuwong C, Ray SS, Thapa RJ, Maki JL, Nogusa S, Shah S, Saleh D, Gough PJ, Bertin J, Yuan J, Balachandran S, Cuny GD, Degterev A. Structure guided design of potent and selective ponatinib-based hybrid inhibitors for RIPK1. Cell Rep. 2015 Mar 24; 10(11):1850-60.
-
Murray M, Hraiki A, Bebawy M, Pazderka C, Rawling T. Anti-tumor activities of lipids and lipid analogues and their development as potential anticancer drugs. Pharmacol Ther. 2015 Jun; 150:109-28.
-
Zhao X, Puszyk WM, Lu Z, Ostrov DA, George TJ, Robertson KD, Liu C. Small molecule inhibitor YM155-mediated activation of death receptor 5 is crucial for chemotherapy-induced apoptosis in pancreatic carcinoma. Mol Cancer Ther. 2015 Jan; 14(1):80-9.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|